drugset / Trial / NCT02887625

Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM

NCT02887625

Unknown 410 enrolled Dr. Muhammad Abdulghani
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare efficacy, safety and durability of combination therapy with pioglitazone plus GLP-1 RA versus basal bolus insulin in poorly controlled T2DM patients on metformin plus sulfonylurea

Timeline

Start
2015-02
Primary completion
2017-05
Completion
2017-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 2 mg Other
Subject Pioglitazone Small molecule 30 mg
Comparator insulin aspart Protein / enzyme biologic
Comparator insulin glargine Protein / enzyme biologic